Design Therapeutics, Inc.
DSGN
$10.30
-$0.74-6.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 59.13M | 57.86M | 55.15M | 49.93M | 44.35M |
| Gross Profit | -59.13M | -57.86M | -55.15M | -49.93M | -44.35M |
| SG&A Expenses | 20.34M | 20.13M | 19.78M | 18.48M | 18.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.47M | 77.99M | 74.93M | 68.40M | 62.38M |
| Operating Income | -79.47M | -77.99M | -74.93M | -68.40M | -62.38M |
| Income Before Tax | -69.79M | -67.45M | -63.49M | -56.20M | -49.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.79 | -67.45 | -63.49 | -56.20 | -49.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.79M | -67.45M | -63.49M | -56.20M | -49.59M |
| EBIT | -79.47M | -77.99M | -74.93M | -68.40M | -62.38M |
| EBITDA | -78.85M | -77.38M | -74.31M | -67.79M | -61.79M |
| EPS Basic | -1.22 | -1.19 | -1.12 | -0.99 | -0.88 |
| Normalized Basic EPS | -0.76 | -0.74 | -0.70 | -0.62 | -0.55 |
| EPS Diluted | -1.22 | -1.19 | -1.12 | -0.99 | -0.88 |
| Normalized Diluted EPS | -0.76 | -0.74 | -0.70 | -0.62 | -0.55 |
| Average Basic Shares Outstanding | 229.30M | 227.25M | 226.92M | 226.62M | 226.35M |
| Average Diluted Shares Outstanding | 229.30M | 227.25M | 226.92M | 226.62M | 226.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |